摘要
背景:在中国,结核病(TB)是威胁生命的疾病,并且新的治疗药物和治疗方案治疗结核病是迫切需要的。 目的:在这项研究中,DNA疫苗表达结核分枝杆菌(MTB)构建了 Rv1419抗原,并对其免疫原性和治疗效果进行了评价。 方法:正常小鼠和结核病模型小鼠肌肉分别每隔两个星期注射免疫和生理盐水三次,质粒载体 pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA 或者 pVAX1-rv1419 DNA。 结果:在三周最后一次免疫后,流式细胞仪检测表明,与生理盐水组和向量组(P<0.05)相比,较高比例的CD4 + T细胞表达IFN-γ(Th1)响应rv1419蛋白在血液从pVAX1 - rv1419 DNA组,表明主导Th1型免疫应答。相比生理盐水对照组,活菌量肺和脾脏均低于0.41 log10的pVAX1 - rv1419 DNA组。此外,DNA疫苗组肺部的病理变化较少。这些结果表明,pVAX1 - rv1419 DNA可为结核病的治疗是有效的,显著增加Th1型细胞免疫反应,抑制结核杆菌的生长 结论:因此pVAX1 - rv1419 DNA是一个可行结核病治疗组合DNA疫苗中的包涵体组成成分。
关键词: DNA疫苗,pVAX1-rv1419 DNA,免疫治疗,结核分枝杆菌,Rv1419 protein,免疫。
Current Gene Therapy
Title:Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis
Volume: 16 Issue: 4
Author(s): Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu and Ning Li, Xueqiong Wu
Affiliation:
关键词: DNA疫苗,pVAX1-rv1419 DNA,免疫治疗,结核分枝杆菌,Rv1419 protein,免疫。
摘要: Background: Tuberculosis (TB) is threatening disease in China and new therapeutic agents and regimens to treat TB are urgently needed.
Objective: In this study, a DNA vaccine expressing Mycobacterium tuberculosis (MTB) Rv1419 antigen was constructed and its immunogenicity and therapeutic effects were evaluated. Method: Normal mice and TB model mice were immunized intramuscularly three times at two-week intervals with saline, plasmid vector pVAX1, M. vaccae vaccine, pVAX1- ag85a (rv3804c) DNA or pVAX1-rv1419 DNA, respectively. Results: At three weeks after the last immunization, flow cytometry showed a higher proportion of CD4+ T cells expressing IFN-γ (Th1) in response to Rv1419 protein in blood from the pVAX1- rv1419 DNA group compared with the saline and vector groups (P<0.05), suggesting a predominant Th1 immune response. Live bacterial loads in lungs and spleens were lower by 0.41 log10 in the pVAX1- rv1419 DNA group than in the saline controls. In addition, pathological changes in the lungs of the DNA vaccinated groups were less. These results suggest that pVAX1- rv1419 DNA could be effective for the treatment of TB, significantly increasing the Th1-type cellular immune response, and inhibiting the growth of MTB. Conclusion: Therefore pVAX1- rv1419 DNA is a candidate for inclusion in a therapeutic combination DNA vaccine against TB.Export Options
About this article
Cite this article as:
Yan Liang, Xiaoyan Zhang, Li Xiao, Xuejuan Bai, Xiaomei Wang, Yourong Yang, Junxian Zhang, Jinying Song, Yinping Liu and Ning Li, Xueqiong Wu , Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161102170123
DOI https://dx.doi.org/10.2174/1566523216666161102170123 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Editorial [Hot Topic: Tuberculosis; Opportunities for Treatment Optimization (Executive Guest Editor: Jan-Willem C. Alffenaar)]
Current Pharmaceutical Design Microbial Efflux Pump Inhibition: Tactics and Strategies
Current Pharmaceutical Design Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis
Current Medicinal Chemistry Bifunctional Anti-HIV/TB Inhibitors: Perspective from In-Silico Design and Molecular Dynamics Simulations
Letters in Drug Design & Discovery Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds Synthesis and Evaluation of Anti-Tuberculosis and Anti-Cancer Activities of Hydrazones and N-Acylhydrazones by Using Sonochemistry, A New General Procedure
Letters in Drug Design & Discovery Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Synthesis, Spectroscopic and Structural Studies of New 2-Substituted 4- Nitroimidazoles
Letters in Organic Chemistry Methods to Profile the Macromolecular Targets of Small Compounds
Current Topics in Medicinal Chemistry Present Status and Future Prospects of Chemotherapeutics for Intractable Infections due to Mycobacterium avium Complex
Current Drug Discovery Technologies Patent Selections
Current Biomarkers (Discontinued) HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Plombage: A Forgotten Surgical Treatment for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry A Review on Genus Alseodaphne: Phytochemistry and Pharmacology
Mini-Reviews in Organic Chemistry Meet Our Editorial Board Member
Current Bioinformatics